{'fraction_non_alphanumeric': 0.04257014398725172, 'fraction_numerical': 0.02879745034431734, 'mean_word_length': 5.255606977572089, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Role of MicroRNAs in Arterial Stiffness and Arterial Calcification. An Update and Review of the Literature

Arterial stiffness is an independent risk factor for fatal and non-fatal cardiovascular events, such as systolic hypertension, coronary artery disease, stroke, and heart failure. Moreover it reflects arterial aging which in many cases does not coincide with chronological aging, a fact that is in large attributed to genetic factors. In addition to genetic factors, microRNAs (miRNAs) seem to largely affect arterial aging either by advancing or by regressing arterial stiffness. MiRNAs are small RNA molecules, ~22 nucleotides long that can negatively control their target gene expression posttranscriptionally. Pathways that affect main components of stiffness such as fibrosis and calcification seem to be influenced by up or downregulation of specific miRNAs. Identification of this aberrant production of miRNAs can help identify epigenetic changes that can be therapeutic targets for prevention and treatment of vascular diseases. The present review summarizes the specific role of the so far discovered miRNAs that are involved in pathways of arterial stiffness.


INTRODUCTION
Arterial stiffness is a characteristic feature of normal arterial aging, but is also associated with accelerated cardiovascular disorders including systolic hypertension, coronary artery disease, stroke, and heart failure, irrespective of other risk factors, such as smoking, dyslipidemia, and diabetes mellitus (Laurent et al., 2006;Mitchell et al., 2010;Shirwany and Zou, 2010;Parthenakis et al., 2017). Another age-related process is arterial calcification, which in turn is a known risk predictor that increases morbidity and mortality in cardiovascular diseases (Goettsch and Aikawa, 2013;Jiang et al., 2017). MicroRNAs (miRNAs) are small (19-25 nucleotides long) non-coding RNAs that downregulate their target gene expression post-transcriptionally via mRNA degradation or translational repression (Pan et al., 2010;Vickers et al., 2014). They are widely studied in recent years and their role in cardiovascular dysfunction is to some extent revealed (Pan et al., 2010;Vickers et al., 2014). Identification of over-or underproduction of miRNAs could be therapeutic targets for prevention and treatment of vascular diseases. The objective of this review is to summarize studies of the most prominent miRNAs that affect major pathways of arterial stiffness and calcification. We searched PubMed for original articles on miRNAs and arterial stiffness or arterial calcification and we also used reviews affiliated to the subject and reviewed their references.

MiRNAs AND ARTERIAL STIFFNESS
Arterial stiffness results from complicated interactions between multiple components of the vessel wall, including extracellular matrix (ECM) composition, vascular smooth muscle cell (VSMC), and endothelial dysfunction. Collagen and elastin are the most important structural proteins of ECM and key regulators of arterial stiffness as they are responsible for blood vessels' strength and elasticity (Zieman et al., 2005;Wagenseil and Mecham, 2012). Reconstruction of ECM, notably increased levels of aberrant types of collagen and reduction of elastin, appears to be the most important mechanism contributing to arterial stiffness (Zieman et al., 2005;Wagenseil and Mecham, 2012;Fleenor and Berrones, 2015). Matrix metalloproteases (MMPs) are endopeptidases which degrade all kinds of ECM proteins. Thus they play a significant role in arterial stiffness via regulating collagen and elastin levels in ECM (Galis and Khatri, 2002;Zieman et al., 2005;Van Doren, 2015). Moreover, advanced glycation end products (AGEs) contribute to arterial stiffness through cross-linking with ECM proteins, including collagen, which reduces vessel's flexibility (Zieman et al., 2005;Fleenor and Berrones, 2015;Xiaomei et al., 2017). Furthermore, many hormones and cytokines are involved in aortic stiffness, such as angiotensin II (Ang II) which promotes arterial stiffness through regulating signaling pathways that result in altered ECM accumulation and increased vascular tone (Rodríguez-Vita et al., 2005;Zieman et al., 2005). Apart from structural abnormalities, VSMC proliferation, migration and calcification, as well as impaired endothelium-dependent dilation through paracrine molecules such as nitric oxide (NO) and endothelin are, also, implicated in the development of arterial stiffness (Zieman et al., 2005;Fleenor and Berrones, 2015). Some of the most prominent miRNAs that affect arterial stiffness through the mechanisms mentioned above are described in the subsequent sections (see Table 1).

MiRNAs AFFECTING EXTRACELLULAR MATRIX PROTEINS
MiR-181b, which seems to decrease with age, plays critical role in ECM remodeling and regulating vascular stiffness and systolic blood pressure (Hori et al., 2017). Chronic down-regulation of miR-181b expression with age was associated with activation of TGF-β (transforming growth factor-beta) signaling in the VSMCs (Hori et al., 2017). TGF-β can initiate multiple effects in the vessels including phenotypic modulation of the VECs (vascular endothelial cells) and VSMCs (Hori et al., 2017). It is also associated with induction of gene expression such as collagen I and III, stimulating the production of ECM (Hori et al., 2017). Furthermore, it also stimulates plasminogen activator-inhibitor production, which inhibits breakdown of ECM, resulting in increased ECM (Hori et al., 2017). MiR-181b inhibits TGF-β signaling pathway by directly inhibiting TGF-βi (transforming growth factor, beta induced) which encodes a protein that interacts with collagen playing a role in cell-collagen interactions (Hori et al., 2017). Similarly, miR-599 suppresses VSMC proliferation and migration and, also, regulates ECM composition by inhibiting type I, type V collagen and proteoglycan via directly repressing TGF-β2 . Interestingly, miR-145 suppresses TGFβ-dependent ECM accumulation and fibrosis by targeting TGFβ receptor II (TGFBR2), while promoting TGFβ-induced smooth muscle cell differentiation (Ning et al., 2015). It seems that a specific miRNA has a selective effect on TGFβ signaling and may facilitate unique downstream events (Ning et al., 2015). Increased expression of a miR-145 mimic in smooth muscle cells resulted in a decrease in TGFβ readout genes, SERPINE1 (PAI-1), and SMAD7 and led to reduced expression of elastin, collagens, and the matrix crosslinking genes, Lox (Lysyl oxidase) and Lox1 (Ning et al., 2015). On the other hand, both TGFβ signaling and miR-145 promote the differentiated phenotype of VSMC and contractile gene expressions, such as a-SMA (smooth muscle α-actin) and SM22α (Ning et al., 2015; see Figure 1).
MiR-29 is considered to be one of the most important miRNAs in regulating ECM composition, as it is known to affect the synthesis of many types of collagen, elastin, MMP-2 and other ECM proteins (Kriegel et al., 2012;Zhu et al., 2013). MiR-29 reduces fibrosis in scleroderma by repressing type I, III, and IV of collagen, while downregulation of miR-29 from TGF-β promotes renal and cardiac fibrosis (Kriegel et al., 2012;Wang B et al., 2012;Zhu et al., 2013). Interestingly enough, however, other studies demonstrated that miR-29 and miR-15 reduce elastin levels during aortic development in the mouse (Ott et al., 2011;Zhu et al., 2013; see Figure 1). Similarly, Zhang et al. showed elastin levels could be increased by inhibiting miR-29a, while collagen levels remained unaffected .

MiRNAs AND ARTERIAL STIFFNESS-CLINICAL STUDIES
Arterial stiffness is most precisely measured by pulse wave velocity (PWV; Laurent et al., 2006). In a study, downregulation of miR-21 was related to decreased levels of arterial stiffness as estimated by PWV in hypertensive patients at baseline and 1 year after antihypertensive treatment (Parthenakis et al., 2017). Interestingly, the effect on arterial stiffness was not correlated with patients' blood pressure levels (Parthenakis et al., 2017).

MiRNAs INDUCING ARTERIAL STIFFNESS THROUGH ANG II
MiR-21 plays an important role in Ang II-mediated fibrosis pathways (Laurent et al., 2006;Lorenzen et al., 2015). In cardiac fibrosis, osteopontin (OPN) that is activated by Ang II upregulates miR-21 through transcription factor AP-1. MiR-21, then, increases fibrosis through enhancing fibroblast activity and ECM accumulation. In this process, miR-21 downregulates PTEN (phosphatase and tensin homolog) and SMAD7, while increases ERK and AKT signaling pathways (Lorenzen et al., 2015; see Figure 1). Inversely, miR-124 exerts an antifibrotic role by reducing pulmonary vascular fibroblast activation by repressing its target gene PTBP1 (polypyrimidine tract-binding protein 1) and subsequently affecting PTEN pathway . PTEN is, also, the target of miR-19b-mediated cardiac fibroblast proliferation and migration (Zhong et al., 2016). However, in another study it was demonstrated that Ang II downregulated miR-19b expression and upregulated connective tissue growth factor (CTGF) expression in cultured cardiomyocytes via an AT1R-dependent pathway, increasing cardiac fibrosis (Gao S. et al., 2014; see Figure 1). All these effects of Ang II were abolished by telmisartan, which is an AT1R (Ang II type 1 receptor) antagonist (Gao S. et al., 2014). CTGF is associated with fibrosis through regulating ECM arrangement (Finckenberg et al., 2003;Gao S. et al., 2014). Finally, Ang II promotes VSMC proliferation by upregulating miR-130a which, in turn, decreases GAX expression, the growth arrest-specific homeobox which exerts an inhibitory role on VSMCs proliferation (Wu et al., 2011). On the contrary, miR-155 overexpression was found to inhibit Ang II-induced viability and proliferation of mouse VSMCs by inducing G1 cell cycle arrest and downregulating the expression of AT1R in VSMCs .
OPN is a protein expessed in many cells, such as osteoblasts and macrophages but it is normally absent from vessel walls. However, under certain conditions, like injury of the wall or presence of atherosclerosis OPN is overexpressed and contributes to the progression of the inflammatory process (Giachelli et al., 1993;Weintraub et al., 2000;Abe et al., 2008;Remus et al., 2013). MiR-181a represses Ang II-mediated OPN increased levels in VSMC as well as Ang II-mediated VSMC adhesion to collagen due to decreased OPN and β1 integrin expression (Weintraub et al., 2000;Remus et al., 2013).

MiRNAs AFFECTING ARTERIAL STIFFNESS THROUGH VASCULAR SMOOTH MUSCLE CELL FUNCTION
Vascular smooth muscle cell (VSMC) is the most prevalent type of cell in vasculature and exert multiple functions influencing arterial stiffness (Sehgel et al., 2013(Sehgel et al., , 2015Fleenor and Berrones, 2015). They are essential regulators of vascular tone through modulating vasoconstriction and vasodilation (Sehgel et al., 2015;. Their main characteristic that contributes to the pathogenesis of arterial stiffness is their ability to switch between two distinguishing phenotypes, a contractile (differentiated) and a proliferative (dedifferentiated) form (Davis-Dusenbery et al., 2011b;Kee et al., 2014). The contractile phenotype is defined as a quiescent state and is characterized of reduced ECM arrangement, suspended proliferation and migration and the expression of some marker genes, such as smooth muscle a-actin (a-SMA), SM22a, smooth muscle myosin heavy chain (MYH11), and myosin light chain kinase (MYLC; Davis-Dusenbery et al., 2011b;Kee et al., 2014;. Conversely, dedifferentiated or synthetic phenotype induces VSMC proliferation, migration, and ECM accumulation resulting in an increase in arterial stiffness (Davis-Dusenbery et al., 2011b;Kee et al., 2014). There seems to be a plethora of miRNAs associated with VSMC proliferation, migration and phenotypic switch in literature and the most prominent of them are listed below (see Table 2).

CRITICAL ROLE OF BMP, TGF-B, AND PDGF-BB
Bone morphogenetic protein (BMP) and transforming growth factor-b (TGF-b) are the major signaling pathways that enhance the contractile phenotype, while, on the other hand, plateletderived growth factor-BB (PDGF-BB) is the primary pathway inducing the proliferative phenotype (Chan et al., 2010). MiR-24, after induced by PDGF-BB, promotes VSMC proliferation through repressing Tribbles-like protein-3 (Trb3), which in turn downregulates SMAD transporters and BMP-TGF-b pathways (Chan et al., 2010). Similarly, miR-26a downregulates TGFb and promotes VSMC proliferation and migration through suppressing the expression of SMAD-1 (Leeper et al., 2011). Inhibition of miR-26a, accelerated VSMC differentiation with a pronounced rise in both MYH11 expression and a-SMA and, also demonstrated increased levels of SMAD-1 and SMAD-4 inhibiting VSMC proliferation and migration (Leeper et al., 2011). Furthermore, PDGF-BB increases the expression of miR-541, which, in turn, promotes VSMC proliferation and invasion by directly repressing IRF7 (Interferon regulatory factor 7; Yang et al., 2016). Also, PDGF-BB can stimulate HIF-1a (hypoxia inducible factor-1a) expression to induce miR-21 upregulation which then inhibits TPM1 expression promoting VSMC proliferation . On the other hand, low levels of miR-96, which is negatively regulated by BMP4, increase Trb3 and promotes the contractile phenotype . MiR-96 is modulated only by BMP signaling and is not affected by PDGF-BB .

MiRNAs AND ARTERIAL CALCIFICATION
Vascular calcification is highly associated with cardiovascular diseases, such as diabetes mellitus, chronic kidney disease, and atherosclerosis, and increases cardiovascular mortality (Goettsch and Aikawa, 2013). Arterial calcification leads to arterial stiffening and hypertension, due to transdifferentiation of VSMCs to a chondrocyte or osteoblast-like phenotype and elastic fiber degradation (Jiang et al., 2017). Here, we mention the major miRNAs that contribute to arterial calcification (see Table 3).

MiRNAs AFFECTING ARTERIAL CALCIFICATION THROUGH METALOPROTEINASES (MMP-2)
One of the pathways of vascular calcification is through dysregulation of matrix metalloproteinase-2 (MMP-2) which is a gelatinase that has an important role in matrix degradation and vascular remodeling (Jiang et al., 2017; see Figure 2). Upregulation of MMP2 expression and activity is shown in VSMCs and animal calcification models, which mediate elastin degradation, resulting in the production of soluble elastin peptides and stimulation of TGF-β1 signaling pathway from the ECM of vessel walls (Jiang et al., 2017). MMP2 upregulation also contributes to bone morphogenetic protein 2 (BMP2) expression in a β-glycerophosphate-induced VSMC calcification model that could increase Runx and Msx2 expression and promote VSMC calcification (Jiang et al., 2017). MMP2 is a direct target gene of miR-29b-3p with a negative correlation between them (Jiang et al., 2017). Overexpression of miR-29b-3p in rat VSMCs resulted in MMP2 downregulation at the protein level and this could lead to decreased arterial and VSMCs calcification (Goettsch and Aikawa, 2013).
Moreover, fibroblast growth factor 23 (FGF23) modulates phosphorus levels, negatively regulates Klotho and is positively correlated to vascular calcification . When Klotho is suppressed (like in rats with vascular calcification) FGF23 could enhance hyperphosphate-induced vascular calcification . FGF23 is a potential target of miR-297a . Low levels of miR-297a upregulate FGF23 and as a consequence suppresses Klotho resulting in further enhancement on vascular calcification ; see Figure 2).

CONCLUSIONS
MiRNAs are a novel class of non-coding RNAs that regulate gene expression. Extensive research during the last decade confirmed the association of miRNAs with cardiovascular diseases. MiRNAs seem to play a significant role in arterial stiffness and calcification through modulating critical pathways and molecules such as TGF-β and BMP signaling, Ang II, MMP activity, Runx, and phenotypic switch of VSMC. Thus, they may be used as therapeutic targets or diagnostic markers in the future to decrease arterial stiffness and prevent the development of cardiovascular diseases. However, it is more than obvious that the molecular biology and pathophysiology is very complex. As mentioned above, many miRNAs might have the same target gene (e.g., Runx2 is suppressed by miR-30b-c but enhanced by miR-32), while a single miRNA might exert multiple functions by targeting more than one genes and affecting different pathways with opposing results (e.g., miR-29, miR-19b and their role in fibrosis). Futhermore, miR-145, one of the most important miRNAs in cardiovascular pathophysiology, decreases arterial stiffness by inhibiting TGF-b signaling while, on the contrary, TGF-b activates miR-145 to promote the contractile phenotype of VSMCs and reduce arterial stiffness as well. Targeting TGF-b through miR-145 might have controversial results. To conclude, additional clinical and laboratory research should be continued for the establishment of miRNAs as treatment targets and biomarkers of cardiovascular diseases. Their emerging role is promising and could result in reducing overall cardiovascular morbidity and mortality in the near future.

AUTHOR CONTRIBUTIONS
SN and MP: Conceived and designed the work, collected the data, and drafted the article; MY: Contributed in drafting the manuscript and critical revision; PZ: Contributed in drafting the manuscript, critical revision, and final approval of the version to be published.